{
    "clinical_study": {
        "@rank": "122661", 
        "arm_group": [
            {
                "arm_group_label": "Nepafenac", 
                "arm_group_type": "Experimental", 
                "description": "Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery."
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension,\n      0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among\n      diabetic subjects following cataract surgery."
        }, 
        "brief_title": "Nepafenac Once Daily for Macular Edema - Study 1", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-Proliferative Diabetic Retinopathy", 
            "Cataract"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Macular Edema", 
                "Retinal Diseases", 
                "Cataract"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Planned cataract extraction by phacoemulsification with implantation of a posterior\n             chamber intraocular lens;\n\n          -  History of Type 1 or 2 diabetes and non-proliferative diabetic retinopathy (NPDR)\n             (mild, moderate, or severe) in the study eye;\n\n          -  Best corrected visual acuity (BCVA) of 73 letters or worse in the study eye with\n             expectation of improvement after surgery;\n\n          -  Understand and sign an informed consent document;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Pre-existing macular edema in the study eye;\n\n          -  History in the study eye of retinal detachment, wet age-related macular degeneration,\n             chronic or recurrent inflammatory eye disease, or prior procedures;\n\n          -  Planned cataract surgery in the fellow eye prior to the Day 90 postoperative study\n             visit or through study exit;\n\n          -  Planned multiple procedures for the study eye during the cataract/intraocular lens;\n\n          -  Use of exclusionary medications, including nonsteroidal anti-inflammatory drugs\n             (NSAIDs) and steroids, as specified in protocol.\n\n          -  Participation in any other clinical study within 30 days of the screening visit;\n\n          -  Females of childbearing potential who are breast feeding, have a positive urine\n             pregnancy test at screening, are not willing to undergo a urine pregnancy test upon\n             entering or exiting the study, intend to become pregnant during the study, or do not\n             agree to use adequate birth control methods for the duration of the study;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "590", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853072", 
            "org_study_id": "C-12-067"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nepafenac", 
                "intervention_name": "Nepafenac Ophthalmic Suspension, 0.3%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Inactive ingredients used as placebo comparator", 
                "intervention_name": "Nepafenac vehicle", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Nepafenac", 
                    "Vehicle"
                ], 
                "description": "1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks", 
                "intervention_name": "Prednisolone acetate ophthalmic suspension", 
                "intervention_type": "Drug", 
                "other_name": "Omnipred\u2122"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Diabetes Type I", 
            "Diabetes Type II", 
            "non-proliferative diabetic retinopathy", 
            "macular edema", 
            "Cataract"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center at 1-888-451-3937 for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Abhijit Narvekar, MS, MBBS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "As measured with Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
            "measure": "Proportion of subjects with BCVA improvement of \u2265 15 letters from preoperative baseline to Day 14 and maintained through Day 90", 
            "safety_issue": "No", 
            "time_frame": "Baseline, up to Day 90"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853072"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "As measured with Spectral Domain Ocular Coherence Tomography (SD-OCT)", 
                "measure": "Proportion of subjects who develop macular edema (defined as \u2265 30% increase from pre-operative baseline in central subfield macular thickness) within 90 days following cataract surgery", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to Day 90"
            }, 
            {
                "description": "As measured with Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
                "measure": "Proportion of subjects with BCVA improvement of \u2265 15 letters from preoperative baseline to Day 90", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 90"
            }, 
            {
                "description": "As measured with Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity charts", 
                "measure": "Proportion of subjects with BCVA improvement of \u2265 15 letters from preoperative baseline to Day 60", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 60"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}